Distribution of HPV types associated with cervical cancers in Scotland and implications for the impact of HPV vaccines

被引：18

作者：

Cuschieri, K. ^{[1
]}

Brewster, D. H. ^{[2
]}

Williams, A. R. W. ^{[3
]}

Millan, D. ^{[4
]}

Murray, G. ^{[5
]}

Nicoll, S. ^{[6
]}

Imrie, J. ^{[7
]}

Hardie, A. ^{[1
]}

Graham, C. ^{[8
]}

Cubie, H. A. ^{[1
]}

机构：

[1] Royal Infirm Edinburgh NHS Trust, Specialist Virol Ctr, Scottish HPV Reference Lab, Edinburgh EH16 4SA, Midlothian, Scotland

[2] NHS Natl Serv Scotland, Informat Serv Div, Scottish Canc Registry, Edinburgh EH12 9EB, Midlothian, Scotland

[3] Royal Infirm Edinburgh NHS Trust, Dept Pathol, Edinburgh EH16 4SA, Midlothian, Scotland

[4] Glasgow Royal Infirm, Dept Pathol, Glasgow G4 0SF, Lanark, Scotland

[5] Aberdeen Royal Infirm, Dept Pathol, Aberdeen AB25 2ZN, Scotland

[6] Ninewells Hosp, Dept Pathol, Dundee DD1 9SY, Scotland

[7] Monklands Gen Hosp, Dept Cytopathol, Airdrie ML6 OJS, Scotland

[8] Wellcome Trust Clin Res Facil, Edinburgh EH4 2XU, Midlothian, Scotland

来源：

BRITISH JOURNAL OF CANCER | 2010年 / 102卷 / 05期

关键词：

HPV; genotyping; Scotland; LESIONS;

D O I：

10.1038/sj.bjc.6605556

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND/METHODS: This study evaluated human papillomavirus (HPV) type prevalence in 370 Scottish invasive cervical cancers (ICCs) using HPV genotyping and HPV mRNA detection. RESULTS: HPV 16 and/or 18 was detected in 72% of cancers overall and in 82% of HPV-positive cancers. HPV 45 and 16 were the most frequently transcribed types. CONCLUSION: A significant reduction in ICC in Scotland should be achieved through the HPV immunisation programme. British Journal of Cancer (2010) 102, 930-932. doi: 10.1038/sj.bjc.6605556 www.bjcancer.com Published online 9 February 2010 (C) 2010 Cancer Research UK

引用

页码：930 / 932

页数：3

共 50 条

[41] High Prevalence of HPV 51 in an Unvaccinated Population and Implications for HPV Vaccines
Bowden, Sarah J.
Ellis, Laura Burney
Kyrgiou, Maria
Fiander, Alison N.
Hibbitts, Samantha
VACCINES, 2022, 10 (10)
[42] Human papillomavirus (HPV) prevalence and HPV type distribution in cervical, vulvar, and anal cancers in central and eastern Europe
Skamperle, Mateja
Kocjan, Bostjan J.
Maver, Polona J.
Seme, Katja
Poljak, Mario
ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA, 2013, 21 (01): : 1 - 5
[43] Nationwide assessment of HPV types in cancers, including anal cancer, in the U.S: implications for current HPV 16/18 and new 9-valent vaccines
Saraiya, Mona
Unger, Elizabeth
Steinau, Martin
Thompson, Trevor
Hernandez, Brenda
Goodman, Marc
SEXUAL HEALTH, 2015, 12 (01) : 89 - 89
[44] Antigen specific cancer immunotherapy for HPV-associated cervical cancers
Lee, BP
Kurman, RJ
Pardoll, DM
Wu, TC
LABORATORY INVESTIGATION, 1997, 76 (01) : 602 - 602
[45] Update on Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology
Hampson, Ian N.
Oliver, Anthony W.
VIRUSES-BASEL, 2024, 16 (08):
[46] Disparities in HPV awareness and knowledge of HPV-associated cancers
Tesfay, Robel
Moser, Richard
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
[47] How will HPV vaccines affect cervical cancer?
Richard Roden
T.-C. Wu
Nature Reviews Cancer, 2006, 6 : 753 - 763
[48] HPV vaccines: the beginning of the end for cervical cancer
Leggatt, Graham R.
Frazer, Ian H.
CURRENT OPINION IN IMMUNOLOGY, 2007, 19 (02) : 232 - 238
[49] Cervical Cancer and HPV Vaccines in Developing Countries
Zarchi, Mojgan Karimi
Behtash, Nadereh
Chiti, Zohreh
Kargar, Saeed
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2009, 10 (06) : 969 - 974
[50] How will HPV vaccines affect cervical cancer?
Roden, Richard
Wu, T. -C.
NATURE REVIEWS CANCER, 2006, 6 (10) : 753 - 763

← 1 2 3 4 5 →